company background image
AM6 logo

Amicus Therapeutics DB:AM6 Stock Report

Last Price

€9.30

Market Cap

€2.8b

7D

-1.1%

1Y

-21.2%

Updated

22 Dec, 2024

Data

Company Financials +

AM6 Stock Overview

A biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. More details

AM6 fundamental analysis
Snowflake Score
Valuation4/6
Future Growth5/6
Past Performance0/6
Financial Health3/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Amicus Therapeutics, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Amicus Therapeutics
Historical stock prices
Current Share PriceUS$9.30
52 Week HighUS$13.20
52 Week LowUS$8.20
Beta0.61
1 Month Change3.91%
3 Month Change-7.00%
1 Year Change-21.19%
3 Year Change-11.43%
5 Year Change5.68%
Change since IPO-5.10%

Recent News & Updates

Recent updates

Shareholder Returns

AM6DE BiotechsDE Market
7D-1.1%-2.9%-2.6%
1Y-21.2%-14.7%6.9%

Return vs Industry: AM6 underperformed the German Biotechs industry which returned -14.7% over the past year.

Return vs Market: AM6 underperformed the German Market which returned 6.9% over the past year.

Price Volatility

Is AM6's price volatile compared to industry and market?
AM6 volatility
AM6 Average Weekly Movement7.2%
Biotechs Industry Average Movement6.8%
Market Average Movement4.8%
10% most volatile stocks in DE Market11.2%
10% least volatile stocks in DE Market2.4%

Stable Share Price: AM6's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: AM6's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
2002517Brad Campbellamicusrx.com

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline.

Amicus Therapeutics, Inc. Fundamentals Summary

How do Amicus Therapeutics's earnings and revenue compare to its market cap?
AM6 fundamental statistics
Market cap€2.81b
Earnings (TTM)-€100.33m
Revenue (TTM)€473.13m

5.9x

P/S Ratio

-28.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
AM6 income statement (TTM)
RevenueUS$493.67m
Cost of RevenueUS$49.43m
Gross ProfitUS$444.24m
Other ExpensesUS$548.93m
Earnings-US$104.69m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.35
Gross Margin89.99%
Net Profit Margin-21.21%
Debt/Equity Ratio217.8%

How did AM6 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 18:53
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Amicus Therapeutics, Inc. is covered by 29 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
John EadeArgus Research Company
Michael UlzBaird
Yun ZhongBerenberg